INO Inovio Pharmaceuticals Inc New

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES                                                                                   
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940                       

1. Name and Address of Reporting Person * DANSEY ROGER D	2. Issuer Name and Ticker or Trading Symbol INOVIO PHARMACEUTICALS, INC. [ INO ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) __X__ Director                    _____ 10% Owner _____ Officer (give title below)    _____ Other (specify below)
(Last)          (First)          (Middle) 660 W. GERMANTOWN PIKE SUITE 110	3. Date of Earliest Transaction (MM/DD/YYYY) 5/13/2021
(Street) PLYMOUTH MEETING, PA 19462 (City)        (State)        (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Common Stock Options	$6.23	5/13/2021		A		54000 (1)		(2)	5/13/2031	Common Stock	54000.0	$0	54000	D
Restricted Stock Unit	(3)	5/13/2021		A		36000 (1)		(3)	(3)	Common Stock	36000.0	$0	36000	D

Explanation of Responses:
(1)	This grant was made pursuant to the issuer's non-employee director compensation policy.
(2)	The vesting schedule for the 54,000 options is as follows: 13,500 shares vested on May 13, 2021; 13,500 shares will vest on May 13, 2022; 13,500 shares will vest on May 13, 2023; 13,500 shares will vest on May 13, 2024.
(3)	Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 36,000 restricted stock units is as follows: 12,000 shares will vest on May 13, 2022; 12,000 shares will vest on May 13, 2023; 12,000 shares will vest on May 13, 2024. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.

Reporting Owners
Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
DANSEY ROGER D 660 W. GERMANTOWN PIKE SUITE 110 PLYMOUTH MEETING, PA 19462	X

Signatures
/s/ Dansey Roger		5/17/2021
**Signature of Reporting Person		Date